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Abstract	
The	clonal	evolution	(CE)	model	and	the	cancer	stem	cell	(CSC)	model	are	two	independent	models	of	cancers,	
yet	recent	data	shows	intersections	between	the	two	models.	This	article	explores	the	impacts	of	the	CSC	model	
on	the	CE	model.	I	show	that	CSC	restriction,	which	depends	on	CSC	frequency	in	cancer	cell	populations	and	on	
the	probability	of	dedifferentiation	of	 cancer	non-stem	cells	 (non-CSC)	 into	CSCs,	 can	 favor	or	 impede	 some	
patterns	of	evolution	(linear	or	branched	evolution)	and	some	processes	of	evolution	(drift,	evolution	by	natural	
selection,	complex	adaptations).	Taking	CSC	restriction	into	account	for	the	CE	model	thus	has	implications	for	
the	way	in	which	we	understand	the	patterns	and	processes	of	evolution,	and	can	also	provide	new	leads	for	
therapeutic	interventions.		
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The	clonal	evolution	(CE)	model	and	the	cancer	stem	cell	(CSC)	model	are	two	models	of	cancer	that	have	an	
ambiguous	 theoretical	 relationship.	 The	 CE	model	 describes	 cancer	 as	 an	 evolutionary	 process	 in	which	 the	
accumulation	of	genetic	and	epigenetic	alterations	results	in	the	diversification	of	cancer	cells	through	space	and	
time	(Figure	1a).	The	CSC	model	states	that	cancers	mimic	tissue	organization	and	emerge	and	develop	only	from	
a	restricted	fraction	of	cancer	cells	with	stem-like	properties	called	CSCs	(Figure	1b).	Historically,	the	CSC	model	
was	framed	in	opposition	to	the	CE	model	(Reya	et	al.	2001;	Wicha	et	al.	2006;	Shipitsin	et	al.	2007;	Pantic	2011).	
Some	investigators	have	since	suggested	that	the	two	competing	models	are	“not	necessarily	mutually	exclusive”	
(Polyak	2007,	3160;	Campbell	and	Polyak	2007;	Lagasse	2008),	 that	one	or	 the	other	could	more	adequately	
explain	different	types	of	cancer	(Adams	and	Strasser	2008;	Shackleton	et	al.	2009),	or	that	the	two	models	are	
complementary	and	should	be	combined	because	 they	each	provide	explanations	of	different	aspects	of	 the	
same	cancer	(Fabian	et	al.	2009;	Greaves	2010;	Lang	et	al.	2015).		
Several	 lines	of	experimentation	have	shown	that	CE	occurs	 in	CSCs	(for	the	first	evidence	see	Piccirillo	et	al.	
2009;	Anderson	et	al.	2011;	Notta	et	al.	2011).	Taking	into	account	the	impact	of	CE	on	CSCs	in	the	CSC	model	
appears	to	be	important	for	at	least	two	reasons.	First,	for	the	therapeutic	strategy	that	emerged	from	the	CSC	
model	 and	 that	 consists	 of	 specifically	 targeting	 the	 CSCs	 during	 cancer	 treatments,	 it	means	 that	 CSCs	 can	
represent	 a	 heterogeneous	 target.	 CSCs	 can	 differ	 both	 synchronically	 (at	 the	 diagnosis	 for	 example)	 and	
diachronically	 (from	 diagnosis	 to	 relapse	 for	 example).	 This	 heterogeneity	 between	 CSCs	 can	 result	 in	 the	
coexistence	of	CSCs	with	various	sensitivities	to	therapies	(e.g.	Meyer	et	al.	2015).	Second,	the	accumulation	of	
new	 mutations	 in	 CSCs	 can	 modify	 their	 properties.	 For	 example,	 additional	 mutations	 could	 lead	 to	 the	
acquisition	 of	 migratory	 ability,	 distinguishing	 “stationary	 CSCs”	 from	 “migrating	 CSCs”	 able	 to	 generate	
metastases	(Brabletz	et	al.	2005;	Bapat	2007;	Odoux	et	al.	2008;	Takebe	and	Ivy	2010).	By	not	taking	into	account	
CE,	the	CSC	model	misses	the	heterogeneity	of	this	CSC	population.	The	incorporation	of	CE	into	the	CSC	model	
is	now	fairly	accepted	(e.g.	Kreso	and	Dick	2014).		
In	contrast,	the	CE	model	still	largely	ignores	the	CSC	model.	Throughout	this	paper,	I	argue	that	CSCs	impact	CE,	
particularly	 through	 a	 phenomenon	 that	 I	 call	 “CSC	 restriction”	 (referring	 to	 the	 fact	 that	 CSCs	 are	 only	 a	
restricted	fraction	of	a	given	cancer),	and	thus	that	the	CE	model	needs	to	incorporate	some	features	of	the	CSC	
model	in	order	to	account	for	all	of	the	consequences	that	CSC	restriction	has	for	CE.		
This	research	took	root	from	previous	philosophical	works.	In	his	book	on	Darwinian	populations,	Godfrey-Smith	
(2009)	 introduced	 a	 framework	 that	 allows	 one	 to	 distinguish	 different	 types	 of	 Darwinian	 populations,	 for	
example	 paradigmatic	 Darwinian	 populations	 in	 which	 evolution	 by	 natural	 selection	 can	 produce	 complex	
adaptations,	i.e.	novel	traits,	versus	marginal	Darwinian	populations	in	which	evolution	by	natural	selection	can	
only	 produce	 simple	 adaptations,	 i.e.	 change	 in	 trait	 frequency.	 Distinguishing	 between	 types	 of	 Darwinian	
populations	depends	on	various	parameters	of	evolution	that	can	be	roughly	measured	(among	which	are	the	
classical	requirements	of	evolution	by	natural	selection	such	as	variation,	heritability,	and	differential	fitness,	as	
well	as	additional	ones	that	can	also	modify	how	Darwinian	a	population	is).	Applying	this	framework	to	cancers,	
Germain	(2012)	highlighted	that	cancer	cell	populations	are	much	less	like	paradigmatic	Darwinian	populations	
than	usually	assumed	and	this	is	in	large	part	due	to	the	CSC	model,	which	appears	as	a	major	factor	that	limits	
the	ability	of	cancer	cells	to	evolve	by	natural	selection	(see	section	1.1).		Germain’s	conclusion	was	the	point	of	
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departure	for	my	work.	If	cancer	cells	are	much	less	like	paradigmatic	Darwinian	populations	than	expected,	then	
what	kind	of	populations	are	they	exactly?	In	this	paper,	I	build	a	framework	similar	to	Godfrey-Smith’s	in	which	
the	measure	of	some	factors	associated	with	CSCs	changes	the	CE	features	of	cancer	cell	populations.	The	two	
factors	of	interest	are	CSC	frequency	(how	many	cancer	cells	are	CSCs?)	and	non-CSC	dedifferentiation	(what	is	
the	probability	of	non-CSCs	becoming	CSCs?),	which	capture	what	I	call	“CSC	restriction”.	The	CE	features	under	
the	 influence	 of	 CSC	 restriction	 are	 processes	 of	 evolution	 (evolution	 by	 natural	 selection	 versus	 neutral	
evolution,	complex	versus	simple	adaptations)	and	patterns	of	evolution	(linear	versus	branched	evolution).	
The	first	section	shows	that	CSC	restriction	limits	evolution	by	natural	selection	(and	more	generally	CE),	prevents	
complex	 adaptations,	 and	 favors	 drift	 and	 linear	 evolution.	 Scientists	 and	 philosophers	 have	 compared	 CSC	
restriction	 to	 other	 phenomena	 well	 known	 in	 evolutionary	 biology	 such	 as	 reproductive	 specialization	 or	
effective	population	size,	raising	the	question	of	whether	we	could	describe	the	impact	of	CSC	restriction	on	CE	
through	classical	parameters	of	evolution.	The	second	section	shows	that	none	of	these	parameters	accurately	
account	for	CSC	restriction,	in	particular	because	it	relies	on	two	different	factors	(CSC	frequency	and	probability	
of	dedifferentiation).	The	last	section	explores	the	potential	biomedical	interests	of	investigating	the	impact	of	
CSC	restriction	on	patterns	of	CE.	
	
	
Figure	1	The	CE	model	and	the	CSC	model.	To	compare	the	CE	model	and	the	CSC	model,	I	propose	two	classical	
representations	of	the	models	(a	and	b,	top	panels)	and	two	more	abstracted	representations	of	these	models	
(a	 and	 b,	 bottom	 panels).	 The	 more	 abstracted	 representations	 are	 useful	 to	 represent	 graphically	 the	
consequence	of	CSC	restriction	on	CE	in	the	next	figure	
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1.	CSC	restriction	impacts	CE		
Before	exploring	the	impact	of	CSCs	on	CE	it	is	necessary	to	have	a	clear	understanding	of	CSCs,	and	in	particular	
of	what	I	call	CSC	restriction.	The	CSC	model	pictures	cancers	as	a	caricature	of	the	normal	tissues	from	which	
they	emerge	(for	a	recent	discussion,	see	Batlle	and	Clevers	2017).	In	most	normal	tissues	in	homeostasis,	there	
is	 a	 hierarchical	 organization	of	 cells	 in	which	 a	 small	 fraction	of	 stem	 cells	 sit	 at	 the	 apex	of	 a	 hierarchy	of	
differentiating	cells.	When	stem	cells	divide,	they	can	give	rise	to	new	stem	cells,	thus	ensuring	the	maintenance	
of	the	stem	cell	pool,	and/or	they	can	differentiate	into	more	mature	cells	(Fig	1b).	In	cancers,	this	organization	
is	altered	(differentiation	can	be	blocked,	biased,	or	amplified),	yet	in	many	cases,	a	hierarchy	is	maintained	and	
only	a	fraction	of	the	cancer	cells	(the	CSCs)	is	able	to	develop	and	maintain	the	tumor.1		
The	explanatory	value	of	the	CSC	model	relies	on	two	premises:	first	that	not	all	cancer	cells	are	CSCs,	and	second,	
that	CSCs	can	be	distinguished	from	non-CSCs	(i.e.	the	observed	functional	difference	between	CSCs	and	non-
CSCs	is	not	stochastic).	The	massive	search	to	identify	CSCs	in	all	cancers	has	produced	conflicting	data	for	both	
premises.	First,	estimated	CSC	frequency	can	vary	by	orders	of	magnitude,	from	very	rare	in	some	cancers	(e.g.	
50	in	106	in	acute	myeloid	leukemia;	Bonnet	and	Dick	1997)	to	very	common	in	others	(e.g.	1	out	of	4	cells	in	
advanced	melanoma;	Quintana	et	al.	2008).	Some	mutations	can	result	in	an	increase	in	CSC	frequency,	indicating	
that	CSC	frequency	can	also	change	during	cancer	progression	(Notta	et	al.	2011;	Clappier	et	al.	2011).	Thus,	the	
CSC	frequency	varies	depending	on	cancer	types	and	stages,	and	it	can	be	measured,	at	least	roughly.2	Second,	
in	 some	 cancers,	 non-CSCs	 can	 dedifferentiate	 into	 CSCs	 (e.g.	 Chaffer	 et	 al.	 2013;	 Koren	 et	 al.	 2015;	 Van	
Keymeulen	 et	 al.	 2015;	Medema	 2017).	 Dedifferentiation	 affects	 the	 quantification	 of	 the	 cancer	 cells	 that	
contribute	 to	cancer	maintenance	and	evolution	 through	 time	because	when	dedifferentiation	 is	possible,	 in	
addition	to	the	actual	CSCs,	the	non-CSCs	represent	a	pool	of	potential	CSCs.	How	many	of	these	non-CSCs	will	
become	CSCs	is	a	variable	that	can	be	measured	as	the	probability	of	dedifferentiation.	Dedifferentiation	of	non-
CSCs	into	CSCs	is	a	process	specific	to	some	cancers	(mostly	observed	in	epithelial	cancers	and	never	observed	in	
blood	cancers	so	far)	and	the	probability	of	dedifferentiation	of	a	non-CSC	into	a	CSC	can	vary	between	cancers	
(e.g.	between	breast	cancers	from	different	cell	of	origin,	Latil	et	al.	2017).		
I	use	the	term	‘CSC	restriction’	to	refer	to	these	two	dynamic	aspects	of	CSCs	(CSC	frequency,	e.g.	their	actual	
number,	and	non-CSC	dedifferentiation,	e.g.	the	probability	that	non-CSCs	dedifferentiate	into	CSCs).	The	level	
of	 CSC	 restriction	 thus	 varies	 in	 different	 cancer	 types	 and/or	 stages.	 CSC	 restriction	 is	 high	 when	 the	 CSC	
frequency	and	the	probability	of	dedifferentiation	are	low	and	vice-versa.	This	section	discusses	the	impact	of	
the	level	of	CSC	restriction	on	CE,	based	on	philosophical,	modeling,	and	biological	literature.		
1.1.	CSC	restriction	limits	evolution	by	natural	selection	and	prevents	complex	adaptations	
                                                   
1	The	cell	of	origin	can	either	be	a	stem	cell	transformed	into	a	CSC	or	a	non-stem	cell	that	reacquired	stemness	
at	transformation	and	became	a	CSC.	For	a	detailed	account	of	the	history,	structure	and	content	of	the	CSC	
model,	see	Laplane	(2014,	2016,	chap	2-4).	
2	CSC	quantification	relies	on	many	experimental	parameters	that	can	all	introduce	biases	(reviewed	in	Kreso	and	
Dick	2014;	Nassar	and	Blanpain	2016).	
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In	 the	CE	model,	 all	 the	 cancer	 cells	 can,	 in	principle,	 evolve.	Cancers	 are	populations	of	 cells	 that	 asexually	
reproduce	through	cell	division.	During	division	they	can	acquire	mutations	that	they	transmit	to	their	daughter	
cells.	The	impact	of	mutations	on	cell	fitness	is	variable	so	that	two	types	of	mutations	are	usually	distinguished	
in	cancers:	passenger	mutations,	i.e.	those	that	do	not	change	the	fitness	of	the	cells,	and	driver	mutations,	i.e.	
those	that	increase	their	fitness	(a	mutation	can	be	passenger	in	one	context	and	driver	in	another).	Cancer	cells	
thus	 fulfill	 the	 minimal	 requirements	 for	 evolution	 by	 natural	 selection;	 they	 are	 populations	 of	 cells	 that	
reproduce	with	some	heritable	variation	in	fitness	(Lewontin	1970;	1978).	Taking	the	CSC	model	 into	account	
makes	 some	 difference	 in	 understanding	 evolution	 in	 cancer	 cells	 because	 it	 indicates	 an	 inequality	 in	 the	
contribution	of	cancer	cells	to	clonal	evolution.	The	CSC	model	distinguishes	two	functionally	distinct	populations	
of	cells,	one	with	a	virtually	unlimited	proliferative	ability	(the	CSCs),	and	the	other	with	a	limited	proliferative	
ability	 (the	 non-CSCs)	 (Fig.	 1b).	 On	 short	 time	 scales	 (days	 to	 weeks)	 this	 functional	 distinction	 makes	 no	
difference.	But	on	 the	 time	scale	of	 the	disease	 (months	 to	years),	 it	makes	a	major	difference	as	mutations	
occurring	in	non-CSCs	are	washed	away	from	the	population	through	exhaustion	of	the	proliferative	ability	of	
these	cells	and	ultimately	cell	death.	Non-CSCs	are	evolutionary	dead-ends	and	only	the	mutations	occurring	in	
CSCs	can	persist	over	time	and	generate	long-standing	subclones	(i.e.	the	various	populations	of	cells	with	the	
same	pool	of	mutations	that	constitute	a	given	cancer)	(Fig.	2	a-b).	The	proportion	of	mutations	that	will	be	able	
to	participate	in	CE	over	the	course	of	the	disease	depends	both	on	the	frequency	of	CSCs	in	the	population	(Fig.	
2c)	and	the	probability	of	dedifferentiation	of	non-CSCs	(Fig.	2d).	This	led	Greaves	to	argue	that	CSCs	are	the	main	
units	of	selection	in	cancers	(Greaves	and	Maley	2012;	Greaves	2013,	2015).	The	question	then	is:	what	difference	
does	it	make	for	CE?	Germain	(2012)	offered	an	answer:	CSC	restriction	limits	evolution	by	natural	selection	and	
makes	complex	adaptations	unlikely.	
The	main	aim	of	Germain	(2012)	was	to	assess	the	role	of	evolution	by	natural	selection	in	cancers.	To	achieve	
this	goal,	he	used	Godfrey-Smith’s	(2009)	famous	account	of	Darwinian	populations	and	applied	it	to	cancers.	
The	 importance	 of	Godfrey-Smith’s	 framework	 for	Germain	was	 that	 it	 allows	 a	more	 precise	 description	 of	
different	types	of	Darwinian	populations	as	functions	of	roughly	measurable	parameters;	the	two	extreme	types	
of	 Darwinian	 populations	 being	 described	 as	 paradigmatic	 Darwinian	 populations	 and	marginal	 Darwinian	
populations.	Evolution	by	natural	selection	can	occur	in	both	but	plays	a	much	greater	role	in	the	former.	The	
general	conclusion	of	Germain	is	that	although	cancer	cells	are	Darwinian	populations,	they	are	not	paradigmatic	
populations	because	there	are	a	number	of	parameters	for	which	they	score	rather	low	(see	Table	1	in	Germain	
2012).	My	 interest	here	 is	 in	 the	 impact	of	CSC	 restriction	on	evolution	by	natural	 selection,	a	question	 that	
Germain	addressed	by	scoring	cancer	cell	populations	with	and	without	taking	into	account	the	CSC	model.	For	
one	parameter,	reproductive	specialization,	taking	the	CSC	model	into	account	makes	a	large	difference	in	how	
the	cancer	cells	score,	and	therefore	on	how	Darwinian	they	are.		
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Figure	2	CE	with	and	without	taking	into	account	CSC	restriction.	(a)	In	the	classical	CE	model,	which	does	not	
take	CSCs	into	account,	all	cancer	cells	are	considered	to	be	units	of	selection.	(b)	When	CSC	restriction	is	taken	
into	account,	only	the	CSCs	are	considered	as	meaningful	units	of	selection	throughout	the	course	of	the	disease,	
because	the	mutations	that	occur	in	non-CSCs	are	washed	away	from	the	population.	(c)	CSC	restriction	depends	
on	 the	 frequency	 of	 CSCs	 and	 can	 vary	 from	 very	 low	 to	 very	 high,	 which	 differentially	 affects	 CE.	 (d)	 CSC	
restriction	also	depends	on	the	probability	of	dedifferentiation	of	non-CSCs	into	CSCs,	as	mutations	occurring	in	
non-CSCs	 are	 not	 washed	 away	 if	 the	 mutated	 cells	 dedifferentiate	 into	 CSCs.	 High	 or	 low	 probability	 of	
dedifferentiation	will	differentially	affect	CE	
	
Reproductive	 specialization	 refers	 to	 the	 germ/soma	 distinction	 and	 related	 phenomena	 in	 which	 only	 a	
sequestered	part	of	the	individual	can	give	rise	to	a	new	individual	through	sexual	or	asexual	reproduction	(the	
germ	 cells),	 while	 the	 rest	 of	 the	 individual	 cannot	 (the	 somatic	 cells)	 (see	 Godfrey-Smith	 2009,	 p.	 92).	 In	
multicellular	organisms,	reproductive	specialization	partially	suppresses	evolution	by	natural	selection	at	the	cell	
level	by	making	the	somatic	cells	evolutionary	dead-ends	(see	Godfrey-Smith	2009,	p.	101).	Germain	argued	that	
the	 coexistence	 of	 CSCs	 and	 non-CSCs	 in	 cancers	 produces	 a	 reproductive	 specialization	 comparable	 to	 the	
germ/soma	distinction:	non-CSCs	are	unable	to	grow	a	tumor	 like	somatic	cells	are	unable	to	produce	a	new	
Accepted for publication in Philosophy and Biology 25.04.2018 
 7 
organism,	whereas	CSCs	are	able	 to	grow	a	 tumor	 like	germ	cells	 are	 capable	of	producing	a	new	organism.	
Greaves	made	a	similar	comparison:		
Darwinian	models	of	cancer	now	need	to	adopt	the	concept	of	cancer	stem	cells;	that	small	population	of	
self-renewing	cells	that	maintain	most	of	the	cancer	cell	population	and,	in	self-replicating,	provide	the	
essential	reservoir	for	further	genetic	variability	and	selection,	equivalent	in	evolutionary	terms	to	germ	
cells	(Greaves	2007,	218).		
Greaves	and	Germain	agree	on	the	phenomenon:	CSC	restriction	is	a	mechanism	by	which	a	number	of	mutations	
are	washed	away	from	the	population	(all	those	that	occur	in	non-CSCs,	dedifferentiation	events	apart,	see	Fig.	
2).	This	phenomenon	also	applies	in	somatic	cells	of	normal	tissues	where	mutations	occurring	in	non-stem	cells	
are	removed	from	the	population	due	to	replication	limits	of	cells	(again	with	the	exception	of	dedifferentiation),	
and	 it	 is	now	a	classic	argument	 that	stem	cells	 limit	cancer	 risk	 (Cairns	1975;	Pepper	et	al.	2007).3	Whether	
reproductive	specialization	accurately	captures	this	phenomenon	is	a	question	that	I	will	address	later	(section	
2.2).	The	important	conclusion	here	is	that	the	higher	the	CSC	restriction (i.e.	the	lower	the	CSC	frequency	and	
the	probability	of	non-CSC	dedifferentiation),	the	less	cancer	cells	are	paradigmatic	Darwinian	populations.	
From	 this	 first	 conclusion,	 a	 second	 conclusion	 follows	 in	 Godfrey-Smith’s	 framework:	 the	 less	 paradigmatic	
cancer	cell	populations	are,	 the	 less	 likely	complex	adaptations	are	 to	occur	because	paradigmatic	Darwinian	
populations	are	characterized	as	those	in	which	natural	selection	can	explain	the	origin	of	novel	traits	(complex	
adaptations)	 whereas	 natural	 selection	 only	 changes	 the	 distribution	 of	 already	 existing	 traits	 (simple	
adaptations)	in	marginal	Darwinian	populations	(see	Godfrey-Smith	2009,	chapter	3).	Complex	adaptations	rely	
on	cumulative	evolution:		
It	can	seem	odd	to	say	that	selection,	which	has	to	do	with	sorting	things	that	already	exist,	can	somehow	
bring	new	things	 into	existence.	But	natural	selection	can	reshape	a	population	 in	a	way	that	makes	a	
given	variant	more	likely	to	be	produced	via	the	immediate	sources	of	variation	than	it	otherwise	would	
be.	Selection	does	this	by	making	intermediate	stages	on	the	road	to	some	new	characteristic	common	
rather	than	rare,	thus	increasing	the	number	of	ways	in	which	a	given	mutational	event	(or	similar)	will	
suffice	 to	produce	 the	 characteristic	 in	question.	 Some	kinds	of	novelty	 can	be	produced	easily	by	an	
evolutionary	process	without	this	role	for	selection,	but	other	kinds—complex	and	adapted	structures—
cannot	(Godfrey-Smith	2009,	43).	
CSC	restriction	impedes	complex	adaptations	by	limiting	cumulative	evolution	in	two	ways	(Germain	2012).	First,	
CSC	restriction	limits	the	size	of	the	cancer	cell	population	in	which	evolutionary	changes	can	accumulate	(Fig.	
2).	Any	complex	adaptations	in	non-CSCs	are	very	unlikely	to	occur	given	that	non-CSCs	can	only	proliferate	for	
short	periods	of	time,	and	thus	mutations	would	be	quickly	lost.	Second,	CSCs	can	be	quiescent	(i.e.	non	dividing	
for	long	periods	of	time),	which	limits	the	possibility	of	cumulative	evolution	in	the	CSC	population	itself.	
                                                   
3	Tomasetti	and	Vogestein	(2015)	argued	that	“variation	in	cancer	risk	among	tissues	can	be	explained	by	the	
number	of	stem	cell	division,”	which	started	a	massive	debate	on	cancer	etiology	and	on	the	causal	contribution	
attributable	to	environment,	heredity,	and	stem	cell	replication	(see	the	latest	response	of	Tomasetti	et	al.	2017).	
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Germain	convincingly	argued	that	the	CSC	model,	and	more	precisely	what	I	call	the	level	of	CSC	restriction,	plays	
an	important	role	in	what	we	can	expect	from	evolution	by	natural	selection	in	cancers.	In	particular,	the	higher	
the	CSC	restriction,	the	less	likely	complex	adaptations	are	to	appear	(Figure	3).4	More	generally,	CSC	restriction	
is	a	way	to	wash	out	a	great	amount	of	the	mutations	that	occur	in	a	given	cell	population.	This	not	only	limits	
evolution	by	natural	selection	but	limits	CE	in	general.	
	
Figure	3	Adaptations	depend	on	CSC	restriction.	The	lower	the	CSC	frequency	and	the	lower	the	probability	of	
non-CSC	dedifferentiation,	the	more	unlikely	complex	adaptations	are	to	occur.	The	black	and	white	gradient	
indicates	directions:	the	lower	the	CSC	frequency	and	the	probability	of	dedifferentiation	of	non-CSCs	into	CSCs,	
the	 less	 likely	complex	adaptations	are.	The	exact	shape	of	the	gradient	remains	to	be	empirically	evaluated.	
Notice	also	that	some	values	are	biologically	absurd	or	equivalent.	For	example,	having	a	CSC	frequency	of	100%	
and	a	probability	of	dedifferentiation	of	1	is	a	bit	absurd,	because	if	there	are	only	CSCs	then	there	are	no	non-
CSCs	to	dedifferentiate.	Similarly,	if	the	probability	of	dedifferentiation	is	1	then	CSC	frequency	cannot	be	0%	
	
1.2.	CSC	restriction	favors	drift	
Germain’s	investigation	focused	on	evolution	by	natural	selection.	As	CE	is	not	restricted	to	evolution	by	natural	
selection,	I	would	like	to	continue	his	investigation	at	a	larger	scale.	This	section	focuses	on	drift.	The	CE	model	
was	originally	framed	with	the	idea	that	cancer	is	a	Darwinian	process	of	gradual	evolution	by	natural	selection.5	
Yet,	since	Germain’s	article	was	published,	evidence	for	neutral	evolution	has	been	reported	in	hepatocellular	
carcinoma	(Ling	et	al.	2015)	and	colorectal	cancers	(Sottoriva	et	al.	2015;	Sottoriva	et	al.	2017).	Applying	a	neutral	
evolution	mathematical	model	to	the	sequencing	data	of	904	cancers	from	14	types,	Williams	et	al.	(2016)	found	
that	 the	 neutral	 model	 fitted	 with	 high	 precision	 323	 of	 them	 (more	 than	 a	 third),	 suggesting	 that	 neutral	
evolution	could	affect	many	more	cancers	than	anticipated.	In	these	cancers,	they	argue,	most	of	the	mutations	
responsible	for	the	cancer	expansion	were	already	present	in	the	first	malignant	cell	and	the	following	evolution	
was	neutral,	a	phenomenon	sometime	referred	to	as	a	“Big	Bang”	model	of	cancer	progression	(Sottoriva	et	al.	
                                                   
4	I	focus	on	mutations	because	they	are	the	usual	traits	that	are	used	to	reconstruct	and	study	the	evolution	of	
cancer	cell	populations,	but	the	argument	would	apply	for	any	heritable	trait.	
5	Here	I	focus	on	the	assumption	that	CE	is	a	process	of	evolution	by	natural	selection	because,	to	the	best	of	my	
knowledge,	no	evidence	suggests	that	CSC	restriction	can	favor	or	limit	punctuated	or	gradual	evolution.	But	the	
assumption	that	CE	is	a	gradual	process	has	been	challenged	by	the	observation	of	several	complex	mutational	
events	that	induce	multiple	mutations	in	a	burst	(e.g.	Stephens	et	al.	2011;	Rausch	et	al.	2012;	Nik-Zainal	et	al.	
2012a;	Baca	et	al.	2013).	The	extent	and	limits	of	the	analogy	with	Eldredge	and	Gould’s	punctuated	evolution	is	
discussed	 in	 Gao	 et	 al.	 	 (2016).	 Markowetz	 (2016)	 suggested	 that	 saltationist	 theories	 such	 as	 the	 hopeful	
monsters	theory	of	Richard	Goldschmidt	might	be	more	relevant	in	cancers.	
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2015;	Amaro	et	al.	2016).6	Another	pan-analysis	also	highlighted	that	negative	selection,	which	is	predominant	
in	the	germ	line,	is	nearly	absent	in	cancer	and	somatic	evolution	(Martincorena	et	al.	2017).	Does	CSC	restriction	
impact	whether	 cancers	 follow	a	pattern	of	neutral	 evolution?	A	model	developed	by	Sottoriva	et	 al.	 (2010)	
suggests	as	much.	In	this	model,	Sottoriva	and	colleagues	observed	that	CE	was	impacted	in	two	ways	when	they	
factored	in	the	CSC	model	(i.e.	by	distinguishing	two	functionally	distinct	populations	of	cancer	cells,	CSCs	and	
non-CSCs).	 First,	 as	 already	discussed	 in	 section	1.1,	CSCs	 repress	CE	by	making	 the	acquisition	of	mutations	
slower.	 Second,	 they	 observed	 a	 different	 clonal	 expansion	 process.	When	 the	 CSC	model	 is	 not	 taken	 into	
account,	a	small	number	of	the	occurring	mutations	were	selected	for	and	invaded	large	portions	of	the	cancer	
cell	population.	In	contrast,	the	implementation	of	the	CSC	model	resulted	in	the	persistence	of	a	large	proportion	
of	 mutations	 that	 remained	 at	 a	 low	 frequency	 in	 the	 population,	 consistent	 with	 neutral	 evolution.	 They	
concluded	“that	the	intrinsic	properties	of	the	CSC	model	might	propel	an	alternative	process	to	natural	selection,	
referred	to	as	genetic	drift”	(Sottoriva	et	al.	2010,	52),	and	attributed	the	occurrence	of	drift	to	sampling	errors	
that	are	much	more	frequent	 in	small	populations—the	CSC	model	stimulates	sampling	error	mechanisms	by	
limiting	the	proportion	of	cells	that	can	acquire	and	maintain	mutations.	
The	conclusion	of	Sottoriva	et	al.	(2010)	that	CSC	restriction	favors	drift	raises	the	question	of	whether	there	is	
higher	 CSC	 restriction	 in	 the	 cancers	 that	 fitted	 the	 neutral	model	 in	Williams	 et	 al.	 (2016).	 To	 answer	 this	
question,	one	would	have	to	align	the	analysis	of	neutral	evolution	from	whole	genome	sequencing	data	with	
scorings	of	 CSC	 frequency	 and	probability	 of	 dedifferentiation	 in	 various	 cancer	 types	 and	also	 in	 cancers	 at	
various	stages	of	progression.	This	would	show	how	a	change	in	CSC	restriction	can	impact	the	processes	of	CE	
(Fig.	4).			
	
Figure	4	CSC	restriction	and	drift.	The	axes	in	this	schematic	diagram	are	the	same	as	the	previous	diagram	(Fig.	
3).	Lower	CSC	frequency	and	probability	of	dedifferentiation	not	only	make	complex	adaptations	very	unlikely,	
they	 also	 favor	 drift.	 Empirical	 comparison	 between	 processes	 of	 evolution	 and	 level	 of	 CSC	 restriction	 are	
required	to	characterize	the	CE	processes	associated	with	each	of	the	points	of	this	two-dimensional	space	
	
1.3.	CSC	restriction	favors	linear	evolution	
                                                   
6	 Whether	 a	 first	 stage	 of	 evolution	 by	 natural	 selection	 precedes	 neutral	 evolution	 is	 a	 matter	 of	 debate	
(Martincorena	et	al.	2015;	Simons	2016).	
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The	CE	model	was	first	represented	as	a	linear	model	of	evolution	wherein	mutations	accumulate	sequentially,	
with	each	new	clone	outcompeting	the	previous	one,	so	that	subclones	accumulating	new	mutations	proceed	
one	 after	 another	 (Fig.	 5a).	 In	 this	 pattern	 of	 CE,	 intratumoral	 heterogeneity	 (ITH)	 is	 diachronic	 rather	 than	
synchronic,	 such	 that	 cells	 accumulate	 mutations	 through	 time	 but	 the	 mutations	 appear	 homogenous	
throughout	the	cell	population	at	any	given	time	(i.e.	at	T1	all	cells	have	mutation	1,	at	T2	all	cells	have	mutations	
1	and	2,	etc.)(e.g.	Hou	et	al.	2012).	In	most	cases	of	linear	evolution	though,	selective	sweeps	appear	incomplete	
and	former	subclones	persist,	but	do	not	give	rise	to	new	subclones	(Fig.	5b)	(e.g.	Merlevede	et	al.	2016).	When	
they	do	give	rise	to	new	subclones,	the	result	is	a	branched	pattern	of	evolution:	mutations	randomly	accumulate	
in	cells	of	various	subclones	continuously	leading	to	the	appearance	of	new	subclones	(Fig.	5c)	(e.g.	Yachida	et	al.	
2016),	which	 is	 the	most	 common	case	 (Andor	et	al.	2016).	 In	 this	 section	 I	develop	 the	hypothesis	 that	CSC	
restriction	might	also	impact	patterns	of	evolution,	and	more	precisely	that	a	higher	level	of	CSC	restriction	might	
favor	linear	evolution.	
	
Figure	5	Three	patterns	of	CE.	 (a)	Linear	homogeneous	CE	 is	characterized	by	the	sequential	accumulation	of	
mutations	 with	 each	 new	 clone	 outcompeting	 the	 previous	 so	 that	 subclones	 accumulating	 new	mutations	
succeed	one	another.	(b)	When	selective	sweeps	are	incomplete	and	former	subclones	persist	without	giving	rise	
to	new	subclones,	the	CS	is	linear	heterogeneous.	(c)	When	former	subclones	accumulate	mutations	and	give	rise	
to	new	subclones,	CE	 is	branched:	mutations	 randomly	accumulate	 in	cells	of	various	subclones	continuously	
leading	to	the	appearance	of	new	subclones	
	
With	similar	cell	division	and	mutation	rates	in	a	fixed	period	of	time,	a	smaller	population	will	accumulate	fewer	
mutations	than	a	bigger	population.	This	is	true	by	definition	if	mutations	occur	during	division.	When	a	mutation	
does	occur,	all	things	being	equal,	it	should	also	have	a	higher	probability	of	invading	the	population,	as	there	are	
fewer	cells	to	outcompete.	There	is	thus	an	inverse	correlation	between	the	probability	of	occurrence	of	new	
mutations	and	 the	probability	of	propagation	of	 the	mutations.	 If	mutations	are	 less	 frequent	and	propagate	
more	easily	in	a	smaller	population,	then	there	is	a	higher	chance	that	the	second	mutation	occurs	on	top	of	the	
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first	mutation	(because	the	first	mutation	is	present	in	a	larger	fraction	of	the	population	at	the	time	of	occurrence	
of	the	second	mutation).	If	the	second	mutation	does	occur	on	top	of	the	first,	and	the	third	on	top	of	the	second,	
then	we	have	linear	evolution.	In	contrast,	in	a	very	large	population,	mutations	propagate	less	easily	and	occur	
more	frequently,	leaving	less	time	for	the	previous	mutation	to	propagate,	and	reducing	the	chance	that	a	new	
mutation	occurs	in	a	cell	bearing	the	previous	one.	If	the	new	mutation	occurs	in	a	cell	that	does	not	have	the	
previous	mutation,	then	we	have	branching	evolution.	Thus,	ceteris	paribus,	smaller	populations	are	more	likely	
to	undergo	linear	evolution	and	larger	populations	are	more	likely	to	undergo	branching	evolution.	As	only	CSCs	
can	participate	in	CE	over	the	course	of	the	disease,	it	is	actually	the	CSC	restriction	that	matters	for	patterns	of	
CE.	Higher	CSC	 restriction	 should	 thus	 favor	 linear	CE,	whereas	 a	 loss	 of	 CSC	 restriction	by	 an	 increased	CSC	
frequency	 and/or	 an	 increased	 probability	 of	 dedifferentiation	 should	 increase	 the	 probability	 of	 branching	
evolution	(Fig	6a).		
The	relationship	between	CSC	restriction	and	patterns	of	CE	has	not	yet	been	studied,	but	there	is	some	indirect	
evidence	in	favor	of	this	hypothesis.	First,	to	the	best	of	my	knowledge,	all	cases	of	linear	evolution	that	have	
been	reported	are	 in	blood	cancers	(supplementary	table	1,	grey	 lines),	which	are	characterized	by	a	 low	CSC	
frequency	and	no	dedifferentiation,	thus	a	high	CSC	restriction.	The	only	exception	comes	from	Shain	et	al.	(2015)	
who	 reported	 linear	 evolution	 in	 the	premalignant	 stages	 of	melanocytic	 neoplasms,	 suggesting	 that	 in	 solid	
tumors,	the	initial	premalignant	stage	could	follow	a	linear	pattern	of	evolution	before	exploding	into	a	branched	
pattern	of	evolution	at	initiation	of	the	malignant	stage	(which	would	be	in	line	with	the	fact	that	cancers	start	
from	the	mutation	of	a	single	cell	and	thus	with	a	small	population	of	CSCs)	(Fig	6b).	Cancers	in	which	non-CSCs	
can	dedifferentiate	and	CSC	 frequency	 is	higher,	 such	as	breast	 cancers,	 colon	cancers,	 advanced	melanoma,	
brain	 cancers,	 osteosarcoma,	 and	 pancreatic	 cancers,	 follow	 branched	 patterns	 of	 evolution	 (supplementary	
table	1).	The	second	kind	of	evidence	comes	from	patterns	of	accumulation	of	mutations	in	normal	tissues	(i.e.	
without	any	overt	cancer	being	diagnosed).	Presence	of	mutations	usually	associated	with	cancers	without	overt	
malignancies	have	been	well	documented	 in	 two	tissues:	skin	of	 the	eyelid	and	blood.	Stem	cell	 restriction	 is	
much	lower	in	the	former	tissue	than	in	the	latter	(higher	stem	cell	frequency	and	dedifferentiation	have	been	
reported	in	skin	epithelium).	Interestingly,	the	patterns	of	mutations	in	these	tissues	are	very	different.	In	the	
eyelid,	Martincorena	et	al.	(2015)	observed	a	high	rate	of	mutations	giving	rise	to	numerous	but	very	small	clones	
(i.e.	clones	with	small	numbers	of	cells).	In	contrast,	in	the	blood	very	few	mutations	have	been	observed,	but	
these	give	rise	to	bigger	clones	(Genovese	et	al.	2014;	Jaiswal	et	al.	2014;	Xie	et	al.	2014).	
To	conclude	this	first	section,	CSC	restriction	limits	evolution	by	natural	selection,	and	more	generally	CE,	prevents	
complex	adaptations,	and	favors	drift	and	linear	evolution	in	a	manner	that	depends	on	CSC	frequency	and	the	
probability	of	dedifferentiation	(Fig	3,	4	and	6).	By	ignoring	the	CSC	model	or	by	considering	it	as	an	independent	
model	of	cancer,	the	CE	model	misses	these	impacts	of	CSC	restriction	on	CE	characteristics.	
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Figure	 6	 Patterns	 of	 evolution	 and	 CSC	 restriction.	 (a)	 Lower	 CSC	 frequency	 and	 lower	 probability	 of	
dedifferentiation	favors	linear	evolution.	(b)	During	disease	progression,	cell	populations	might	move	in	this	two-
dimensional	space.	A	loss	of	CSC	restriction	through	an	increase	in	CSC	frequency	and/or	increase	in	probability	
of	dedifferentiation	might	favor	a	transition	from	a	linear	CE	to	a	branched	CE	
	
2.	Traditional	parameters	of	evolution	do	not	accurately	describe	the	consequences	of	CSC	restriction	for	CE	
The	first	section	showed	that	the	CE	model	should	take	 into	account	the	CSC	model,	and	more	precisely	CSC	
restriction,	because	it	can	affect	both	the	patterns	and	the	processes	of	CE.	This	distinction	between	CSCs	and	
non-CSCs	and	its	 impact	on	CE	resemble	some	phenomena	already	well	known	and	described	in	evolutionary	
biology.	Scientists	and	philosophers	have	discussed	the	resemblance	with	various	parameters	of	evolution	such	
as	heredity	(Greaves	2013),	reproductive	specialization	(Germain	2012;	Greaves	2013),	and	effective	population	
size	(e.g.	Merlo	et	al.	2006;	Pepper	et	al.	2009;	Sottoriva	et	al.	2010;	Lipinski	et	al.	2016;	Lean	and	Plutynski	2016).	
This	section	presents	and	discusses	these	comparisons	as	well	as	additional	ones	(bottleneck	and	dependence	of	
fitness	on	intrinsic	properties).	I	argue	that	none	of	these	parameters	are	entirely	satisfactory	to	describe	the	
impact	of	CSC	restriction	on	CE	and	show	that	the	difficulties	come	from	the	fact	that	CSC	restriction	depends	on	
two	factors:	the	CSC	frequency	and	the	probability	of	dedifferentiation	of	non-CSCs	into	CSCs.		
2.1.	CSC	restriction	and	heredity	
Referring	to	Lewontin’s	classical	minimal	requirement	for	evolution	by	natural	selection,	Greaves	has	argued	that	
it	is	the	lack	of	heredity	that	suppresses	CE	in	non-CSCs,	so	that	only	CSCs	are	genuine	units	of	selection	in	cancers	
(e.g.	Greaves	2013,	104).	This	claim	relies	on	a	misunderstanding	of	the	parameter	of	heredity.	Heredity,	as	a	
parameter	of	evolution,	refers	to	the	fidelity	of	heredity	at	each	generation.	So	what	is	scored	in	heredity	is	the	
“similarity	between	parent	and	offspring,	due	to	causal	role	of	the	parents”	(Godfrey-Smith	2009,	39).	In	cancers,	
the	 fidelity	 of	 heredity	 largely	 depends	 on	 the	 quantity	 of	mutations,	which	 is	 highly	 variable.	 For	 example,	
comparing	30	cancer	types,	Alexandrov	et	al.	(2013)	reported	a	mutational	load	ranging	from	about	0.001/Mb	to	
more	 than	400/Mb.	Whereas	melanoma	can	present	 thousands	of	mutations,	 and	 thus	a	very	 low	 fidelity	of	
heredity	during	cell	division,	very	few	mutations,	if	any,	were	reported	in	ependymomas	(a	pediatric	tumor	of	the	
central	nervous	system)	 indicating	a	high	fidelity	of	heredity	 (Mack	et	al.	2014).	These	differences	depend	on	
several	factors	such	as	genetic	instability,	or	exposure	to	mutagenic	agents.	For	example,	the	fidelity	of	heredity	
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is	far	lower	in	lung	cancers	of	smokers	than	of	non-smokers	(Alexandrov	et	al.	2016).	CSC	restriction	plays	little	
role	 in	fidelity	of	heredity.	What	Greaves	meant	by	 lack	of	heredity	was	that	non-CSCs	can	only	give	rise	to	a	
limited	number	of	generations	of	cells	and	that	only	CSCs	can	reproduce	in	the	long-term,	a	fact	we	all	agree	on	
but	struggle	to	depict	appropriately.	
2.2.	CSC	restriction,	reproductive	specialization	and	bottleneck	
Referring	to	Godfrey-Smith’s	now	famous	parameters	of	evolution,	Germain	(2012)	claimed	that	CSC	restriction	
changes	the	degree	of	reproductive	specialization	(see	section	1.1).	I	agree	that	there	is	an	analogy	between	germ	
line	sequestration	in	multicellular	organisms	and	CSC	restriction	in	cancers.	There	is,	in	both	cases,	a	division	of	
labor	 that	has	massive	 impacts	on	 the	 long-term	 fitness	of	 the	 cells.	But	 this	 analogy	has	 several	 limitations.	
Reproductive	 specialization	 refers	 to	 the	germ/soma	distinction,	or	 equivalent	phenomena.	 It	 relies	on	 three	
conditions.	 There	 is	 a	 reproductive	 specialization	when:	 (1)	 there	 is	 reproduction;	 (2)	 only	 a	 part	 of	 the	 cell	
population	is	involved	in	this	reproduction;	and	(3)	these	cells	are	the	germ	cells,	which	are	distinct	from	somatic	
cells,	that	is,	they	belong	to	a	separated	cell	line.	
Whether	there	is	reproduction	within	cancers	is	a	debatable	matter.	Metastases	could	be	a	candidate	(see	Lean	
and	Plutynski	2016;	Germain	and	Laplane	2017),	but	my	argument	is	that	CSC	restriction	impacts	patterns	and	
processes	of	CE	at	the	cellular	level,	regardless	of	the	formation	of	metastases.	One	could	then	argue	that	cell	
lineages	that	make	up	each	tumor	are	 individuals	that	reproduce.	 In	a	sense,	each	CSC	gives	rise	to	a	 lineage	
containing	a	body	of	non-CSCs.	When	a	CSC	self-renews	and	produces	a	new	CSC	that	gives	rise	to	a	new	lineage,	
then	do	we	have	a	case	of	reproduction?	Whether	each	lineage	can	count	as	an	individual	seems	debatable	to	
me	given	the	absence	of	integration.7	But,	if	we	agree	that	there	is	a	genuine	case	of	reproduction	here,	then	we	
also	meet	the	second	criteria	for	reproductive	specialization,	namely	that	only	a	part	of	the	cells	constituting	the	
individual	are	involved	in	the	reproduction,	here	the	CSCs.	However,	we	then	face	a	limitation	in	the	analogy	with	
regard	to	the	third	criterion:	CSCs	and	non-CSCs	are	not	two	separated	cell	lines	like	somatic	and	germ	cells	are.	
While	germ	line	cells	are	sequestered,	CSCs	(as	well	as	normal	stem	cells)	are	not,	as	the	CSCs	give	rise	to	the	
non-CSCs.	For	CE,	this	might	be	considered	as	a	negligible	problem	when	the	probability	of	dedifferentiation	of	
non-CSCs	into	CSCs	is	null.	But	it	becomes	a	major	difference	as	soon	as	non-CSCs	can	become	CSCs.	In	this	case	
the	distinction	between	germ	line	and	soma	can	no	 longer	apply.	 If	 there	 is	reproduction,	then	 it	 is	of	a	very	
different	kind,	one	that	would	involve	a	bottleneck.		
A	bottleneck	is	when	reproduction	occurs	from	only	a	small	part	of	the	parental	organism	(see	Godfrey-Smith	
2009,	chapter	5).	At	first	sight,	bottleneck	and	reproductive	specialization	might	seem	very	similar,	as	both	are	
processes	that	wash	away	some	mutations,	which	is	exactly	what	the	CSC	vs.	non-CSC	distinction	does.	However,	
they	differ	in	their	consequences	for	evolution:	reproductive	specialization	prevents	any	mutation	occurring	in	
the	somatic	cells/non-CSCs	from	being	transmitted	to	the	next	generation,	whereas	a	bottleneck	does	not	as	
virtually	any	cell	can	be	transmitted	to	the	next	generation.	Thus,	in	cases	where	non-CSCs	can	dedifferentiate	
                                                   
7	There	are	some	feedback	loops	between	mature	cells	and	CSCs	(e.g.	Reynaud	et	al.	2011),	but	those	are	not	
restricted	to	their	own	lineages	and	in	some	cases,	like	blood	cancers,	the	cells	from	different	lineages	are	all	
mixed	and	moving	around.	
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into	CSCs,	the	question	becomes	whether	CSC	restriction	(CSC	frequency	and	probability	of	dedifferentiation)	
equates	 to	 the	 degree	 of	 bottleneckishness.	 If	 each	 CSC	 lineage	 counts	 as	 an	 individual,	 then	 the	 degree	 of	
bottleneckishness	 is	always	the	same:	each	individual	starts	with	only	one	CSC,	whatever	the	probability	 is	of	
dedifferentiation.	If	the	degree	of	bottleneckishness	is	always	the	same	while	the	CSC	restriction	can	vary,	then	
it	cannot	describe	the	degree	of	CSC	restriction.			
Hence,	the	reproductive	specialization	parameter	could	only	capture	the	impact	of	CSC	restriction	on	CE	in	cases	
where	the	probability	of	dedifferentiation	is	null,	with	the	limitations	in	the	analogy	that	CSCs	and	non-CSCs	are	
not	separate	lineages	and	provided	that	lineages	do	reproduce.	One	could	then	argue	that	the	frequency	of	CSCs	
equates	 to	 the	 degree	 of	 reproductive	 specialization.	 But	 CSC	 restriction	 also	 depends	 on	 the	 probability	 of	
dedifferentiation,	and	when	non-CSCs	can	dedifferentiate	into	CSCs,	then	there	is	no	reproductive	specialization,	
but	rather	a	bottleneck.	However,	as	the	degree	of	bottleneckishness	is	stable	(one	cell,	the	CSC),	it	is	unlikely	to	
do	 a	 better	 job	 of	 capturing	 the	 impact	 of	 CSC	 restriction	 on	 CE,	 which	 changes	 with	 the	 probability	 of	
dedifferentiation	and	CSC	frequency.8		
2.3.	CSC	restriction	and	dependence	of	fitness	on	intrinsic	properties	
Besides	being	a	case	of	reproductive	specialization,	Godfrey-Smith	(2009)	also	describes	germ	line	sequestration	
as	a	case	of	low	dependence	of	fitness	on	intrinsic	properties,	which	quantifies	how	much	reproductive	success	
depends	on	intrinsic	properties	(e.g.	the	genetic	content	of	the	cells)	versus	extrinsic	properties	(e.g.	the	location	
in	a	particular	environment).	Low	dependence	of	fitness	on	intrinsic	properties	represses	evolution	by	natural	
selection,	as	in	the	case	of	germ	line	sequestration,	because	the	difference	in	the	long-term	fitness	of	the	germ	
line	cells	compared	to	somatic	cells	is	not	due	to	intrinsic	properties	(that	can	be	positively	selected	for)	but	to	
the	fact	that	the	cells	ended	up	being	part	of	one	or	another	group	of	cells	during	development.	If	reproductive	
specialization	does	not	exactly	capture	CSC	restriction,	can	dependence	of	 fitness	on	 intrinsic	properties	do	a	
better	job?	The	question	here	is	whether	the	difference	in	fitness	between	CSCs	and	non-CSCs	is	due	to	context	
or	intrinsic	properties.	In	other	words,	is	CSC	identity	intrinsic	or	extrinsic?		
If	non-CSCs	can	dedifferentiate	into	CSCs,	it	means	that	under	certain	circumstances	in	some	cancers,	stemness	
can	 be	 acquired.	 But	 the	 ability	 or	 not	 to	 dedifferentiate	 is	 not	 sufficient	 to	 answer	 our	 question,	 as	 the	
microenvironment	can	play	varying	roles	in	both	cases.		In	previous	work,	I	have	shown	that	two	questions	must	
be	distinguished	to	understand	the	identity	of	stem	cells,	including	CSCs:	(1)	can	non-stem	cells/non-CSCs	acquire	
stemness	and	dedifferentiate	into	stem	cells/CSCs?	(2)	Is	stemness	acquisition	and/or	maintenance	dependent	
upon	the	microenvironment?	Depending	on	the	answers	to	these	questions,	which	are	specific	to	tissues	and	
cancers,	four	different	identities	can	be	distinguished	for	the	property	of	stemness	(Laplane	2016):		
1. Categorical:	stemness	is	purely	intrinsic.	
                                                   
8	I	am	very	grateful	to	both	anonymous	reviewers	for	the	thorough	discussion	that	has	lead	to	this	version	of	the	
argument.		
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2. Dispositional:	stemness	is	an	intrinsic	property	whose	expression	depends	on	extrinsic	stimuli	from	the	
microenvironment.	
3. Relational:	stemness	is	an	extrinsic	property	induced	and	controlled	by	the	microenvironment.	
4. Systemic:	stemness	is	an	extrinsic	property	controlled	at	the	cell	population	level.	
In	the	last	three	cases,	the	fitness	of	the	CSCs	depends,	to	various	degrees,	on	context	(which	can	include	the	
tumor-microenvironment,	clone-clone	interactions,	and	feedback	loops	between	mature	cells	and	CSCs).	In	cases	
where	stemness	is	a	relational	property,	being	a	CSC	depends	on	the	location	of	the	cancer	cells.	Dependence	of	
fitness	on	intrinsic	properties,	in	this	instance,	is	very	low.	It	is	higher	in	cases	where	stemness	is	a	dispositional	
property	because	being	 a	CSC	depends	on	 intrinsic	properties,	 although	 it	 is	 still	 limited	by	 the	 fact	 that	 the	
reproductive	success	of	each	CSC	is	regulated	by	the	microenvironment.	In	cases	where	stemness	is	a	systemic	
property,	being	a	CSC	depends	on	various	factors	including	intrinsic	properties	such	as	stochastic	gene	expression	
and	extrinsic	properties	such	as	feedback	loops	and	other	collective	processes;	here,	dependence	of	fitness	on	
intrinsic	properties	hangs	upon	 the	 relative	contribution	of	 intrinsic	and	extrinsic	 factors	 in	 stemness.	Finally,	
dependence	of	fitness	on	intrinsic	properties	is	high	in	cases	where	stemness	is	a	categorical	property	because	
the	difference	 in	 fitness	 in	 the	 long	 term	 is	mainly	due	 to	 intrinsic	properties.	 Thus,	 the	 identity	of	CSCs	 can	
provide	interesting	insights	for	CE,	for	example,	cancers	in	which	stemness	is	a	categorical	property	should	be	
more	likely	to	evolve	by	natural	selection	than	cancers	in	which	stemness	is	a	relational	property.	But,	the	degree	
of	dependence	of	fitness	on	intrinsic	properties	does	not	correlate	with	the	degree	of	CSC	restriction.	
2.4.	CSC	restriction	and	effective	population	size	
Some	biologists	and	philosophers	have	suggested	that	CSC	restriction	simply	limits	the	effective	population	size,	
as	opposed	to	the	census	population	size	(e.g.	Merlo	et	al.	2006;	Pepper	et	al.	2009;	Sottoriva	et	al.	2010;	Lipinski	
et	al.	2016;	Lean	and	Plutynski	2016).		
In	fact,	the	question	of	whether	the	entire	neoplasm	or	a	minority	of	neoplastic	cells	is	capable	of	
self-renewal	is,	at	least	in	part,	a	question	merely	of	the	effective	population	size	of	the	evolving	
cells	in	a	neoplasm	(Pepper	et	al.	2009,	66).	
The	claim	here	is	that	the	effective	population	size	is	the	size	of	the	CSC	population.	The	lower	the	CSC	frequency	
is,	the	greater	the	difference	is	between	the	effective	population	size	and	the	census	population	size,	and	the	
smaller	the	effective	population	size	is.	Reducing	the	effective	population	size	impacts	evolutionary	processes:	
smaller	populations	are	considered	more	prone	to	drift,	as	sampling	error	can	more	easily	lead	to	the	expansion	
of	clones	with	no	clear	survival	benefit	 (see	section	1.2).9	More	generally,	 the	arguments	 that	CSC	restriction	
represses	 CE,	 favors	 drift,	 prevents	 complex	 adaptations,	 and	 favors	 linear	 evolution,	 could	 be	 reduced	 to	 a	
question	 of	 effective	 population	 size,	 if	 the	 probability	 of	 dedifferentiation	 is	 null.	 But	 if	 non-CSCs	 can	
dedifferentiate	 into	 CSCs	 at	 any	 time,	 then	 the	 actual	 CSC	 frequency	 poorly	 represents	 the	 cells	 that	 can	
                                                   
9	The	 idea	 that	drift	dominates	 selection	 in	 small	populations	has	been	debated,	 see	 for	example	 the	 recent	
debate	between	Clatterbuck,	Sober	and	Lewontin	(2013)	and	Brandon	and	Fleming	(2014).	
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meaningfully	contribute	to	CE,	and	thus	also	poorly	represents	the	effective	population	size.	The	probability	of	
dedifferentiation	of	non-CSCs	into	CSCs	is	then	once	more	a	major	factor	for	CE.		
Taken	together,	these	difficulties	highlight	that	CSC	restriction	is	not	easily	captured	by	any	classical	parameter	
of	evolution,	in	particular	because	of	the	difference	between	CSC	frequency	and	dedifferentiation,	as	well	as	the	
four	different	possible	identities	of	CSCs	(see	section	2.3).	To	account	for	the	impact	of	CSC	restriction	on	CE,	one	
needs	to	measure	both	the	frequency	of	CSCs	and	the	probability	of	dedifferentiation	of	non-CSCs.	
3.		Biomedical	relevance	of	the	impact	of	CSC	restriction	on	CE	
The	first	section	showed	that	the	degree	of	CSC	restriction	could	favor	or	impede	various	processes	and	patterns	
of	 evolution,	 and	 in	 particular	 that	 it	 can	 favor	 linear	 or	 branched	 evolution.	 Scientists	 regularly	 investigate	
whether	CE	is	linear	or	branched	but	give	limited	attention	to	the	difference	it	makes.	Why	should	we	care	about	
the	 impact	 of	 CSC	 restriction	 on	 linear	 or	 branched	 evolution?	 In	 this	 section,	 I	 argue	 that	 the	 relationship	
between	CSC	 restriction	and	patterns	of	CE	 is	worth	exploring	 for	 the	biomedical	 sciences,	 first,	because	 the	
patterns	of	CE	can	inform	us	about	CSC	restriction,	and	in	particular	about	the	probability	of	dedifferentiation	
that	 is	 currently	 difficult	 to	 measure;	 second,	 because	 it	 offers	 original	 opportunities	 for	 new	 therapeutic	
strategies.	
3.1.	From	CE	patterns	to	CSC	restriction	
CE	patterns	are	mainly	used	to	infer	either	the	relative	fitness	of	each	subclone	in	a	given	environment	or	their	
age.	In	cases	of	evolution	by	natural	selection	the	bigger	subclones	are	the	ones	with	the	greatest	reproductive	
success	 in	that	environment.	 In	cases	of	neutral	evolution,	the	bigger	subclones	are	the	oldest.	 In	addition	to	
these	inferences,	I	have	argued	in	this	paper	that	the	pattern	of	CE—linear	or	branched—is,	at	least	in	part,	a	
function	of	CSC	restriction.	If	I	am	right,	then	reconstruction	of	the	CE	could	be	informative	about	CSC	restriction.	
This	 could	be	valuable	 in	cancers	 in	which	one	of	 the	 two	parameters	of	CSC	 restriction—CSC	 frequency	and	
probability	of	dedifferentiation—	is	unknown.	For	example,	in	a	set	of	cancers	of	a	given	type	(e.g.	melanomas),	
if	we	can	measure	the	CSC	frequency	and	reconstruct	the	CE	tree,	we	may	be	able	to	infer	if	dedifferentiation	
occurred	or	not	and,	if	it	occurred,	whether	it	is	a	marginal	or	frequent	process	(i.e.	whether	the	probability	of	
dedifferentiation	 is	 high	 or	 low).	 This	 is	 far	 from	 trivial	 given	 that	 the	 current	 technologies	 allow	 far	 better	
approximations	of	CE	patterns	and	of	CSC	frequencies	than	of	the	probability	of	dedifferentiation.	
3.2.	From	CSC	restriction	to	CE	patterns:	therapeutic	consequences	
What	 difference	 does	 it	 make	 if	 CE	 is	 linear	 or	 branched?	 Is	 one	 or	 the	 other	 better	 for	 the	 patients?	 The	
immediate	 relevance	of	distinguishing	CE	patterns	 is	 that	 the	coexistence	of	multiple	 subclones	 is	a	cause	of	
therapy	resistance.	The	more	subclones	there	are,	the	greater	the	risk	of	therapy	resistance.	If	my	hypothesis	
that	a	higher	CSC	restriction	should	favor	a	more	linear	and	simpler	pattern	of	CE	is	right,	then	patients	would	
benefit	 from	 any	 complementary	 therapies	 that	 can	 increase	 CSC	 restriction.	 Opportunities	 to	 control	 CSC	
restriction	are	emerging.	The	most	recent	examples	are	Cimmino	et	al.	(2017)	and	Agathocleous	et	al.	(2017),	
who	showed	that	vitamin	C	regulates	the	frequency	of	normal	or	malignant	hematopoietic	stem	cells.		
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Conversely,	any	therapy	that	would	decrease	CSC	restriction	should	be	avoided.	Hypomethylating	agents	(HMAs)	
are	used	as	first	line	treatment	in	chronic	myelomonocytic	leukemia	(CMML),	myelodysplastic	syndromes	(MDS),	
and	acute	myeloid	leukemia	(AML)	of	the	elderly,	when	patients	are	not	eligible	for	stem	cell	transplantation.	
But	HMAs	have	 also	been	used	 in	 a	 very	different	 context,	 unrelated	 to	 cancer,	 to	 induce	 cell	 plasticity	 and	
dedifferentiation	(e.g.	Mikkelsen	et	al.	2008;	Chandrakanthan	et	al.	2016).	Some	studies	also	suggest	that	HMAs	
can	decrease	stem	cell	restriction	in	the	normal	hematopoietic	system,	either	by	increasing	their	frequency	or	by	
inducing	dedifferentiation	 (Suzuki	et	al.	2004;	Chung	et	al.	2009).	 If	 they	also	decrease	CSC	 restriction	 in	 the	
patients	(a	question	I	am	currently	experimentally	investigating	in	my	lab),	then	the	prediction	of	this	study	is	
that	HMA	treatment	must	favor	more	CE,	more	adaptability,	and	more	complex	patterns	of	evolution.	This	could	
help	to	explain	the	transiency	of	patients’	responses	to	HMAs	and	the	frequent	progression	of	CMML	and	MDS	
into	AML.	If	progression	under	treatment	were	due	to	the	loss	of	CSC	restriction,	then	one	way	to	maintain	the	
benefit	 of	 the	 drug	 without	 its	 counterproductive	 effects	 would	 be	 to	 couple	 it	 with	 a	 drug	 increasing	 CSC	
restriction.	Many	drugs	(none	targeting	CSCs)	are	currently	tested	in	combination	with	HMAs	without	yet	leading	
to	improvement	in	overall	survival	(Ball	et	al.	2017).	In	this	current	clinical	context,	my	work	suggests	that	drugs	
acting	on	CSC	restriction	are	worth	investigating	too.	 
Conclusion	and	perspectives	
While	the	inclusion	of	CE	into	the	CSC	model	has	been	fairly	well	addressed	in	the	literature	(Kreso	and	Dick	2014;	
Nassar	and	Blanpain	2016),	showing	in	particular	that	CSCs	are	a	heterogeneous	target	for	anti-CSC	therapies,	
the	 impact	of	 the	CSC	model	 on	CE	has	been	poorly	 explored.	 This	 article	 shows	 that	CSC	 restriction,	which	
depends	on	CSC	 frequency	and	the	probability	of	non-CSC	dedifferentiation,	 impacts	CE	 in	several	ways.	The	
higher	the	CSC	restriction,	the	more	it	can:	
• limit	CE;	
• limit	evolution	by	natural	selection;		
• prevent	complex	adaptations;	
• favor	drift;	
• favor	linear	evolution.	
A	 loss	of	CSC	 restriction	 (higher	CSC	 frequency	and/or	higher	probability	of	dedifferentiation)	during	disease	
progression	will	thus	favor	more	adaptability,	making	the	inclusion	of	CSC	restriction	into	the	CE	model	highly	
relevant	for	biomedical	research.	
Incorporating	 CSC	 restriction	 into	 the	 CE	 model	 faces	 several	 difficulties,	 opening	 perspectives	 for	 further	
philosophical	 and	 biological	 research.	 First,	within	 current	 experimental	 limitations,	 it	 is	 difficult	 to	 properly	
quantify	the	number	of	CSCs	and	the	probability	of	dedifferentiation	within	a	cancer	at	any	given	time.	Thus	CSC	
restriction	 can	only	be	 roughly	estimated.	Current	 improvements	 in	 lineage	 tracing	 technologies	will	 provide	
great	help.	Estimation	of	the	probability	of	dedifferentiation	of	non-CSCs	into	CSCs	is	also	becoming	an	urgent	
need	that	remains	too	poorly	addressed.	
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Second,	recent	work	has	shown	that	under	homeostatic	conditions,	progenitor	cells	(the	first	daughter	cells	of	
stem	cells),	can	support	the	production	of	all	the	blood	cells	for	much	longer	than	initially	thought	(Sun	et	al.	
2014;	Busch	et	al.	2015).	This	raises	a	new	question	for	cancers:	are	CSCs	the	only	meaningful	units	of	selection	
in	CE?	Depending	on	the	duration	of	the	disease,	progenitor	cells	might	also	be	taken	into	account	as	part	of	CSC	
restriction,	which	would	change	the	measure	of	CSC	restriction.	
Third,	the	analysis	presented	in	this	article	is	made	ceteris	paribus.	My	point	is	that	every	other	parameter	being	
equal,	a	difference	in	CSC	restriction	will	affect	CE.	A	further	question	would	be	whether	other	parameters,	like	
the	rate	of	mutation	and	of	proliferation,	as	well	as	the	role	of	the	microenvironment	and	more	generally	the	
physical	constraints	of	the	tissues	outweigh	some	of	the	impact	of	CSCs	on	the	patterns	and	processes	of	CE.	
Finally,	this	article	focuses	on	the	impact	of	CSC	restriction	on	CE.	If	correct,	then	the	next	question	is	how	can	
we	 act	 on	 CSC	 restriction	 in	 order	 to	 limit	 CE	 and	 disease	 progression?	 To	 answer	 this	 question	 requires	
investigating	the	two	factors	of	CSC	restriction:	CSC	frequency	and	non-CSC	dedifferentiation.	What	causes	an	
increase	 in	the	frequency	of	CSCs	within	a	given	cancer,	and	how	can	this	 increase	 in	the	number	of	CSCs	be	
avoided	or	reduced?	What	induces	dedifferentiation	of	non-CSCs	into	CSCs	and	how	can	we	prevent	it?	These	
questions	 require	 a	 thorough	 investigation	 of	 the	 role	 of	 the	 microenvironment	 and	 of	 population-level	
processes.	The	microenvironment	can	play	a	decisive	role	in	the	proliferation	of	CSCs	and	their	ability	to	generate	
a	clone	(Arranz	et	al.	2014;	Dong	et	al.	2016).	Mature	cancer	cells	(non-CSCs)	can	also	play	an	important	role	in	
the	proliferation	of	the	CSCs	through	the	cytokines	they	secrete	(Reynaud	et	al.	2011;	Welner	et	al.	2015),	raising	
the	 question	 of	 interactions	 between	 subpopulations,	 and	more	 generally	 indicating	 the	 need	 to	 investigate	
multilevel	selection	processes	(Sprouffske	et	al.	2013;	Lean	and	Plutynski	2016).		
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